Biotechnology

Curative Biotechnology, Inc.

Curative Biotechnology, Inc. released FY2024 Q3 earnings on November 14, 2025 (EST), actual revenue USD 0, actual EPS USD -0.1464

Curative Biotechnology, Inc. released FY2025 Q3 earnings on November 14 (EST) with actual revenue of USD 0 and EPS of USD -0.1149

Curative Biotechnology, Inc. released FY2025 Q1 earnings on May 19, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.162

Curative Biotechnology, Inc. released FY2024 Q1 earnings on May 19 (EST), actual revenue USD 0, actual EPS USD -0.1837

Curative Biotechnology, Inc. released FY2023 Q4 earnings on April 15 (EST) with actual revenue of USD 0 and EPS of USD -0.0048

Curative Biotechnology, Inc. released FY2024 Annual Earnings on April 15, 2025 (EST), Actual Revenue: USD 0, Actual EPS: USD -0.5827

Curative Biotechnology, Inc. released FY2022 Annual Earnings on May 6, 2024 (EST), actual revenue USD 0, actual EPS USD -1.434

Curative Biotechnology, Inc. released FY2023 earnings on May 6, 2024 (EST) with actual revenue of USD 0 and EPS of USD -1.3177

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

GCL Global

Silexion Therapeutics

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Bristol-Myers Squibb Company

CUBT

Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply of Metformin Topical Ophthalmic Therapy | CUBT Stock News

StockTitan

CURATIVE BIOTECHNOLOGY INC

Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply of Metformin Topical Ophthalmic Therapy | CUBT Stock News

Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting | CUBT Stock News

Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting | CUBT Stock News

INCR

ICCM

CUBTD

Photocure leverages EAU 2026 trials to cement role in precision bladder cancer care

Tip Ranks

Intercure

Icecure Medical

iShares US Medical Devices

SPDR S&P Health Equip

Photocure leverages EAU 2026 trials to cement role in precision bladder cancer care

Curative Biotechnology, Inc. announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for its patent application related to a novel pharmacological target for treating retinal degeneration. This patent supports the company's metformin-based eye drop program, which aims to address degenerative eye diseases in both humans and canines. The patent includes 22 allowed claims and is expected to formally issue soon. Curative is focused on developing therapeutic approaches for rare diseases, with plans for a clinical trial in 2026 for its AMD treatment.

Curative Biotechnology Announces Canadian Patent Allowance | CUBT Stock News

Curative Biotechnology, Inc.(CUBT.US)

Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply of Metformin Topical Ophthalmic Therapy | CUBT Stock News

Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting | CUBT Stock News

Photocure leverages EAU 2026 trials to cement role in precision bladder cancer care

Curative Biotechnology Announces Canadian Patent Allowance | CUBT Stock News